The Miami Stem Cell Therapy Podcast

As global interest in Muse cell science has grown, so has the number of products marketed using similar terminology. Understanding what actually separates authentic Dezawa MuseCells from look-alike products has become an increasingly important part of evaluating any claim in this space, whether the audience is a patient, a physician, or a researcher.

The term Muse cell refers to a specific, scientifically defined subpopulation of stem cells, short for multilineage-differentiating stress-enduring cell, discovered by Professor Mari Dezawa at Tohoku University in 2010. As awareness of that discovery has spread, the term has sometimes been adopted by products with little or no connection to the original research or its licensed manufacturing pathway. This is not unusual when a genuinely novel discovery becomes widely known. Vocabulary tends to spread faster than rigor, and in cell-based medicine, where the products involved are introduced directly into the human body, that gap carries real consequences.

Origin is the first place to look. Authentic Dezawa MuseCells are perinatal in origin, derived from donated umbilical cord tissue through a well-documented, ethically sourced process. Look-alike products may come from far less consistent or poorly disclosed sources, which affects both their biological properties and the ethical framework surrounding how they were obtained.

Manufacturing is the second, and perhaps most decisive, factor. Authentic Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder for the Dezawa protocol. That includes documented chain of custody, sterility testing, and consistent identification through specific biological markers, SSEA-3 paired with CD105 for bone marrow-derived cells, or SSEA-3 paired with CD45 for cells sourced from peripheral blood. Products that cannot produce this kind of documentation cannot be verified as authentic, regardless of how confidently they are marketed.

Validation is the third factor. Legitimate research has described properties such as non-tumorigenic pluripotency and a tissue-homing mechanism guided by the S1P-S1PR2 signaling pathway, findings that appear in peer-reviewed scientific literature connected to the original Dezawa protocol. Look-alike products often borrow this language, describing similar mechanisms, without being able to show that their specific product underwent comparable scientific validation.

Put together, these three factors, origin, manufacturing, and validation, form a practical checklist. Is the product traceable to documented, ethically sourced tissue? Is it manufactured under verifiable GMP protocols with consistent marker identification? And is it connected to published research or documented clinical data, rather than general statements borrowed from someone else's science? Physicians incorporating Muse cell research into their practice, and patients evaluating treatment options, are both better served by insisting on clear answers to these questions rather than relying on branding or terminology alone. In a field still building its evidence base, that kind of scrutiny is what ultimately separates credible science from marketing.

Stem cell tourism describes the practice of traveling internationally to access regenerative medicine treatments that may be unavailable, restricted, or still in early research phases at home. As global interest in Muse cell science has grown, including in Dezawa MuseCells, so has the number of patients weighing whether to travel for access to this research. Understanding how to evaluate that decision matters as much as understanding the science itself.

It helps to start with a clear distinction. Stem cell tourism is not inherently unsafe. Legitimate international clinics operate under credible manufacturing and clinical oversight standards, and for some patients, traveling abroad genuinely opens access to research unavailable elsewhere. The challenge is that the same global landscape enabling legitimate access also allows clinics with far less rigorous standards to market similar-sounding therapies without comparable safeguards.

Published research on international stem cell tourism consistently points to one central recommendation: evaluate treatment options based on published clinical evidence, not testimonials or promotional claims. This is especially relevant for Muse cell science, where genuine research, involving properties such as non-tumorigenic pluripotency and a tissue-homing mechanism guided by the S1P-S1PR2 signaling pathway, exists alongside a marketplace where similar terminology is sometimes used loosely by clinics offering different or lower-quality products.

Transparency is one of the most useful screening tools available to patients. A credible clinic should be willing to explain, in specific terms, how its cells are sourced and manufactured, and should be equally willing to discuss the current limitations of the evidence alongside any potential benefits. Authentic Dezawa MuseCells are manufactured under Good Manufacturing Practice protocols by MUSE Cell Innovations and identified using specific biological markers. A transparent clinic should confirm these details without hesitation.

Language itself is worth watching closely. The term Muse cell has real scientific specificity, referring to a defined subpopulation identified by markers such as SSEA-3 combined with CD105 or CD45. In a global marketplace, however, similar language sometimes gets applied to products that have not undergone comparable research or manufacturing oversight. Patients can protect themselves by comparing how a clinic describes its product across different materials, a website, a consent form, and a direct conversation with staff. Inconsistencies between those sources are often a sign that marketing has moved faster than documentation.

Finally, researchers increasingly recommend a practical test: ask whether the treating clinic is willing to communicate directly with a patient's physician at home, both before and after treatment. That willingness, or its absence, tends to say a great deal about whether a clinic is built around genuine clinical rigor or primarily around attracting patients. Combined with a focus on published evidence, transparent sourcing, and precise language, this kind of physician-to-physician dialogue gives patients a structured, evidence-based way to navigate a field that continues to expand rapidly around the world.

Regulatory pathways for stem cell-based therapies vary widely from country to country, and that variation has led a growing number of patients to consider traveling abroad for access to Muse cell research, including Dezawa MuseCells. While international access can open doors that would otherwise be closed, it also places more responsibility on the patient to evaluate what they are actually being offered.

The most important factor to assess is physician qualification. Patients should look for clear evidence of medical licensure, relevant specialty training, and specific experience with Muse cell protocols rather than general stem cell treatment. A credible physician will be able to speak to how many patients they have treated using a given protocol, what outcomes have been documented, and whether they participate in the broader professional community, including the conferences where manufacturing standards and clinical evidence are actively debated.

Manufacturing verification matters just as much as physician credentials. Not every product marketed using similar terminology is manufactured to the same standard. Authentic Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder, and identified using specific biological markers, SSEA-3 combined with CD105 for bone marrow-derived cells, or SSEA-3 combined with CD45 for cells sourced from peripheral blood. Before booking any travel, patients should request documentation confirming these standards are actually being met.

Continuity of care is one of the most commonly overlooked considerations. Because Muse cell research remains investigational, follow-up monitoring after treatment is essential, not optional. Patients should ask, before they travel, how a clinic plans to coordinate care once they return home. Will records be provided in a usable, translated format? Is there a clear point of contact if questions arise weeks or months later? Will a physician at home be willing to provide supportive care for someone who was treated elsewhere?

There are also warning signs worth watching for. Clinics that guarantee specific outcomes, discourage second opinions, avoid detailed questions about manufacturing, or apply pressure toward a fast booking decision should prompt additional scrutiny. By contrast, clinics operating in good faith tend to welcome those same questions and provide documentation readily, because transparency is part of how credible regenerative medicine research is conducted.

Taken together, these considerations point toward a simple approach: confirm that a clinic uses licensed, authentic protocols, verify the treating physician's relevant credentials and experience, request documentation of manufacturing and quality control standards, and clarify exactly how follow-up care will work before committing to travel. None of this removes the underlying uncertainty that comes with any investigational therapy, but it significantly reduces the risk of encountering a misrepresented or poorly regulated product, and it puts the patient in a stronger position to make a genuinely informed decision.

Orthopedic medicine has long relied on a familiar progression: conservative treatment first, surgery when that fails. In recent years, a middle path has opened up in the form of biologic therapies, treatments designed to support the body's own repair processes before more invasive options become necessary. Increasingly, that conversation includes Muse cells, and specifically, Dezawa MuseCells.

Muse cells were first identified in 2010 by Professor Mari Dezawa at Tohoku University. The name stands for multilineage-differentiating stress-enduring cells, a rare subpopulation found naturally in bone marrow, connective tissue, and peripheral blood. Two properties make them relevant to orthopedic research. First, they are pluripotent without being tumorigenic, meaning they can differentiate into multiple tissue types without the tumor-forming risk associated with some other pluripotent cells. Second, they exhibit what researchers describe as intelligent tissue homing, migrating toward sites of injury through a signaling pathway involving sphingosine-1-phosphate and a receptor called S1PR2.

For joints, tendons, and connective tissue, this homing behavior has generated theoretical interest. Damaged musculoskeletal tissue often has limited blood supply, which slows natural healing. Researchers are studying whether cells capable of locating and responding to injury signals might have relevance in that context, alongside other orthobiologic approaches already in use, such as platelet-rich plasma and conventional mesenchymal stem cell therapies.

Manufacturing plays a central role in how this research is evaluated. Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder for the Dezawa protocol. Cells are identified using specific markers, SSEA-3 paired with CD105 for bone marrow-derived cells, or SSEA-3 paired with CD45 for cells isolated from peripheral blood. That level of standardization matters because orthopedic tissue is highly variable, and consistency in what is being studied is essential to drawing reliable conclusions.

Joint preservation, the broader clinical goal of delaying or avoiding joint replacement surgery, is where much of this research is aimed. Physicians exploring biologic strategies for musculoskeletal conditions are watching Muse cell research develop alongside other established approaches, with an emphasis on building outcome data rather than making early promises. Current applications remain investigational, and researchers are careful to frame ongoing work as part of a longer evidence-building process rather than a finished clinical solution.

Looking ahead, the future of Muse cell research in orthopedics will likely depend on the same factors driving progress across regenerative medicine broadly: standardized protocols, transparent outcome tracking, and rigorous comparison against existing treatments. As that evidence base grows, musculoskeletal medicine may increasingly incorporate findings from this research, provided that manufacturing authenticity and clinical documentation remain the foundation of how the field moves forward.

Regenerative medicine conferences around the world have a new fixture on their agendas: Muse cells, and specifically, Dezawa MuseCells. Named for the researcher who discovered them, Professor Mari Dezawa of Tohoku University, these cells were first identified in 2010 as a rare subpopulation of stem cells found naturally in bone marrow, connective tissue, and peripheral blood. Since then, interest has moved from laboratories into conference halls, where physicians now gather to discuss what these cells are, how they are manufactured, and what the science actually supports.

Four themes tend to dominate these sessions. The first is manufacturing quality. Dezawa MuseCells are processed under Good Manufacturing Practice protocols by MUSE Cell Innovations, the licensed global technology holder for the Dezawa protocol. The cells are perinatal in origin, meaning they are derived from donated umbilical cord tissue, and they are identified using specific biological markers. Cells isolated from bone marrow are confirmed using SSEA-3 alongside CD105, while those isolated from peripheral blood are confirmed using SSEA-3 alongside CD45. For physicians, this level of specificity is not a technical footnote. It is the foundation of trust in any biologic product.

The second theme is patient selection. Because Muse cells behave differently than conventional mesenchymal stem cells, physicians spend considerable conference time discussing which patients might be appropriate candidates for investigational approaches, what diagnostic steps should come first, and how outcomes should be tracked and documented. Part of what makes this conversation necessary is the unusual biology involved. Muse cells are pluripotent, meaning they can differentiate into cell types from all three embryonic germ layers, yet research has shown they do not form tumors, a property that sets them apart from many other stem cell types under investigation.

That leads to a mechanism researchers frequently highlight: tissue homing. When introduced into the body, Muse cells appear to migrate on their own toward sites of injury, guided by a signaling pathway involving a molecule called sphingosine-1-phosphate, produced by damaged tissue, and a receptor known as S1PR2. This intelligent homing behavior is one of the most discussed findings in current Muse cell research, and it continues to generate scientific curiosity about how the cells might support the body's own repair processes.

The third theme is evidence development. Regenerative medicine as a field is still building the body of clinical data needed to move promising science into widely accepted practice. Conference tracks increasingly cover clinical-grade products such as CL2020, along with updates on research into conditions like stroke, myocardial infarction, and acute respiratory distress syndrome. Physicians attending these sessions are encouraged to view current findings as part of an ongoing research trajectory rather than a finished conclusion.

Finally, conferences look ahead. Discussions increasingly touch on where this research may lead, including orthopedic applications involving joints and connective tissue, and broader systemic approaches to tissue support. Across every session, one message remains constant. Protocol authenticity and physician education are what separate credible regenerative medicine research from unsubstantiated claims. As global interest in Muse cells continues to grow, medical conferences remain the place where that distinction is made clearest.

Today’s episode is a little different. Instead of focusing on the science itself, we’re looking at a trend among the physicians who study it: a growing number of regenerative medicine specialists are actively seeking out structured education on Muse cells.

Why now? A few things seem to be driving it. First, the published research base has simply grown. Since Professor Mari Dezawa and colleagues first characterized Muse cells in 2010, the volume of peer-reviewed literature covering their biology, their mechanism, and early clinical trial data has expanded steadily across specialties including cardiology, neurology, and dermatology. That gives physicians an actual body of evidence to study, rather than relying on marketing claims or anecdotal reports.

Second, patient interest is rising. As public awareness of regenerative medicine grows, physicians report fielding more direct questions from patients about biologic therapies, Muse cell-based approaches included. That creates real demand for physicians to be able to explain, accurately, what is and isn’t established about a given therapy.

Third, and this one is important: terminology in this space isn’t always tightly regulated. Products described using similar language can differ substantially in origin, manufacturing standard, and scientific validation. So part of physician education now involves learning to distinguish an authentic, well-documented protocol from a similarly named product that may not have the same evidence behind it.

So what does this education actually look like in practice? A lot of it happens at regenerative medicine conferences, which give physicians direct access to researchers presenting original data and a chance to ask detailed technical questions. Beyond that, many physicians build an ongoing habit of tracking peer-reviewed literature as it’s published, across the relevant specialty journals, rather than treating a single training session as sufficient. And increasingly, physician education includes direct review of a specific manufacturer’s protocol documentation: how the cells are sourced, isolated, validated, and quality-tested before clinical use.

That last point connects to a theme that comes up again and again in this space: standardization. Consistent isolation methods, validated potency and purity testing, and reproducible manufacturing processes matter because published research is generated using specific, validated protocols. A product using similar terminology but a different or unvalidated protocol may not produce comparable results, even if it sounds the same on paper.

Ultimately, this translates into better patient conversations. Physicians who’ve done the work of reviewing the underlying literature are better positioned to set accurate expectations, explaining clearly which applications remain investigational, which trial phases have been reached, and what a given patient should realistically expect.

Groups like STEMS Health, a regenerative medicine practice in Miami Beach, Florida, reflect this broader trend, prioritizing ongoing education grounded in peer-reviewed research and manufacturing transparency. As with every episode, this content is for general educational purposes only and isn’t medical advice. Any regenerative medicine procedures mentioned may be considered investigational or not FDA approved for certain conditions, so speak with a licensed healthcare provider about what’s appropriate for you.

That wraps up today’s episode. Thanks for listening.

If you’ve listened to this podcast before, you’ve probably heard us mention a property called tissue homing. Today, let’s actually unpack what that means and how it works.

In cell-based research, homing refers to the ability of cells, once administered, to migrate toward a specific site in the body rather than distributing randomly or getting stuck somewhere unrelated to the injury. That distinction matters more than it might sound. Standard mesenchymal stem cells, for instance, are known to become passively trapped in the lungs after intravenous injection, regardless of where the actual injury is. A cell type capable of active, targeted homing offers a more direct path to the treatment site, without needing surgical delivery.

Muse cells, identified by Professor Mari Dezawa and colleagues, are the property most consistently discussed in this context. Here’s the mechanism: when tissue is damaged, anywhere in the body, it releases a lipid signaling molecule called sphingosine-1-phosphate, or S1P. Researchers describe it as a kind of universal distress signal, with local levels rising at the site of damage, whether that damage comes from a heart attack, a spinal cord injury, or radiation exposure. Muse cells express a specific receptor for that signal, called S1PR2, which allows circulating cells to detect elevated S1P and travel toward it. In several animal studies, differentiated cells that arrive this way have gone on to integrate into existing tissue structures, including neuronal circuits studied in spinal cord and brain research.

This matters to researchers for a couple of practical reasons. Because the S1P signal is released by damaged tissue generally, rather than being specific to one organ, the homing mechanism has been studied across cardiac, neurologic, dermatologic, and gastrointestinal research, all building on the same underlying biology rather than starting from separate premises each time. And because some injury sites are diffuse, hard to access, or simply not good candidates for direct injection, a cell type that can be delivered intravenously and still find its way to the target offers a practical advantage.

So how do scientists actually verify this happens? In the lab, researchers typically label Muse cells with fluorescent or luminescent markers before administering them, then track their location over time to confirm whether, and how much, they accumulate at the injury site rather than elsewhere. Some studies have gone further, using receptor-blocking agents to show that when the S1PR2 pathway is inhibited, homing and the associated tissue repair drop off significantly, which is fairly strong evidence for how central that mechanism actually is.

A couple of caveats are worth mentioning. Not every infused Muse cell reaches the injury site. Published research indicates only a portion do, with the rest distributed elsewhere or cleared through normal processes. And this homing behavior does appear to be a distinguishing feature of Muse cells specifically. Standard mesenchymal stem cells that lack the SSEA-3 marker have shown less effective homing through this same pathway in research studies.

STEMS Health, a regenerative medicine practice based in Miami Beach, Florida, follows this line of research as part of tracking how the science develops. As always, this is general educational content, not medical advice, and related procedures may be investigational or not yet FDA approved. Consult a licensed healthcare provider for guidance specific to you.

Thanks for listening, and we’ll see you in the next episode.

Today we’re zooming out a bit to talk about where regenerative medicine as a field seems to be headed, and why one particular cell type, the Muse cell, keeps coming up in that conversation.

Over the past decade, regenerative medicine research has been moving away from one-size-fits-all protocols and toward approaches that account for differences between patients: the type of injury, the stage of disease, and individual biology. That shift has been driven partly by better diagnostic imaging and biomarker tools, which let researchers get a clearer picture of who might respond to a given treatment, and when.

Cell-based therapies sit right in the middle of that trend, but their usefulness depends heavily on whether a given cell type can actually be delivered precisely and consistently. This is where Muse cells, first identified by Professor Mari Dezawa, draw particular interest. Because they can detect an injury signal called sphingosine-1-phosphate through a receptor called S1PR2, they’re able to be given intravenously and still concentrate at a site of tissue damage, whether that’s the heart, the spinal cord, or the skin. That’s a meaningful difference from therapies that require direct injection or surgical placement at a specific location.

Still, there are real open questions researchers are working through before this potential becomes an established clinical reality. How many cells are actually needed for a given condition, and does repeated dosing outperform a single administration? How long do differentiated cells persist in the body, and is any reparative effect sustained over years rather than months? Do promising early results in one condition, like heart attack recovery, generalize to other organ systems? Can manufacturing of a frozen cell product scale up to meet demand across multiple treatment centers? And how will regulators evaluate a therapy with such a broad range of potential applications?

Researchers also tend to frame this work as part of a bigger-picture shift toward personalized regenerative medicine, one where diagnostics help determine which patients are likely to benefit from a given intervention, and where protocols developed in one specialty, say cardiology, inform work happening in neurology, orthopedics, or dermatology. It’s a similar logic to what’s already played out in precision oncology, where biomarker-driven treatment selection has become standard practice.

It’s worth being direct about the current state of things, though. Personalization in this context mostly describes a research direction, not an established, individualized treatment model. Most published clinical trials still use standardized dosing for a given condition. And there’s no evidence yet that Muse cells require the kind of donor matching used in organ transplants, though that’s an area of continued study rather than settled practice.

Groups like STEMS Health, a regenerative medicine practice in Miami Beach, Florida, follow this research as part of understanding where the field may be going next. As always, this is general information, not medical advice, and any regenerative procedures discussed may be investigational or not yet FDA approved for certain conditions. 

Thanks for listening, and we’ll catch you next time.

Let’s talk today about a distinction that comes up often in stem cell research: the difference between cells that are engineered to become pluripotent, and cells that are simply found that way in the body already.

Most of the attention-grabbing stem cell science over the past two decades has centered on induced pluripotent stem cells, or iPSCs, first developed by Shinya Yamanaka. Making an iPSC involves taking an adult cell and introducing specific transcription factors to push it back into an embryonic-like state. It’s a clever workaround for the ethical and supply issues tied to embryonic stem cells, but it introduces its own technical challenges, including the risk that if any of those reprogrammed cells remain undifferentiated after transplant, they can form a type of tumor called a teratoma. Embryonic stem cells carry similar tumorigenicity concerns of their own.

Muse cells take a different path entirely. They were first identified in 2010 by Professor Mari Dezawa and colleagues, and they occur naturally in adult tissue, including bone marrow, fat tissue, and peripheral blood. Researchers identify them using a surface marker called SSEA-3, and because they already exist in the body in this state, isolating them is a matter of sorting cells that are already there, rather than reprogramming or engineering anything. No viral vectors, no transcription factor reprogramming, no embryonic tissue involved.

That distinction turns out to matter for a few practical reasons researchers care about. First, tumorigenicity: published animal studies to date haven’t shown Muse cells forming teratomas, in contrast to the documented risk associated with iPSCs and embryonic stem cells. Second, manufacturing complexity: because there’s no reprogramming or differentiation-induction step required, the production process is simpler than what’s needed for engineered pluripotent cells. Third, immune compatibility: Muse cells express a marker called HLA-G, which is associated with immune tolerance, similar to mechanisms seen in placental tissue. Researchers have studied whether that property might reduce the need for donor matching or immunosuppressive drugs in certain contexts. And fourth, there’s the homing behavior we’ve covered on this show before, the ability of Muse cells to travel to an injury site through a signaling pathway involving sphingosine-1-phosphate and a receptor called S1PR2, a property not shared by standard mesenchymal stem cells to the same degree.

Put together, natural origin, an apparent absence of tumor formation in current studies, and built-in injury homing make Muse cells a distinct subject of study compared to both conventional mesenchymal stem cells and engineered pluripotent cell types. That’s part of why groups like STEMS Health, a Miami Beach-based regenerative medicine practice, keep a close eye on this area of the literature.

Thanks for tuning in, and we’ll see you next time.

Welcome back to the show. Today we’re taking a closer look at a naturally occurring stem cell that keeps showing up in research papers across a surprising range of medical specialties: the Muse cell, discovered in 2010 by Professor Mari Dezawa and her colleagues at Tohoku University.